Cell-surface residence of sphingosine 1-phosphate receptor 1 on lymphocytes determines lymphocyte egress kinetics.
about
Actions of a picomolar short-acting S1P₁ agonist in S1P₁-eGFP knock-in miceThe SphKs/S1P/S1PR1 axis in immunity and cancer: more ore to be minedSphingosine-1-phosphate receptor 1 signalling in T cells: trafficking and beyondFingolimod for the treatment of neurological diseases-state of play and future perspectivesMoesin controls clathrin-mediated S1PR1 internalization in T cellsPreclinical Metabolism, Pharmacokinetics and In Vivo Analysis of New Blood-Brain-Barrier Penetrant Fingolimod Analogues: FTY720-C2 and FTY720-MitoxySphingosine-1-phosphate receptor 1 in classical Hodgkin lymphoma: assessment of expression and role in cell migration.Defective sphingosine 1-phosphate receptor 1 (S1P1) phosphorylation exacerbates TH17-mediated autoimmune neuroinflammationSphingosine 1-phosphate signaling in bone remodeling: multifaceted roles and therapeutic potentialFTY720 (s)-phosphonate preserves sphingosine 1-phosphate receptor 1 expression and exhibits superior barrier protection to FTY720 in acute lung injury.The sphingosine 1-phosphate transporter, SPNS2, functions as a transporter of the phosphorylated form of the immunomodulating agent FTY720.Multiple-dose tolerability, pharmacokinetics, and pharmacodynamics of ponesimod, an S1P1 receptor modulator: favorable impact of dose up-titration.Effect of ponesimod, a selective S1P1 receptor modulator, on the QT interval in healthy individuals.Sphingosine-1-phosphate and immune regulation: trafficking and beyondOzanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1 ) and receptor-5 (S1P5 ) agonist with autoimmune disease-modifying activity.Individual variation of human S1P₁ coding sequence leads to heterogeneity in receptor function and drug interactionsFTY720 inhibits tubulointerstitial inflammation in albumin overload-induced nephropathy of rats via the Sphk1 pathway.S1PR1 Tyr143 phosphorylation downregulates endothelial cell surface S1PR1 expression and responsiveness.Pharmacological relevance and potential of sphingosine 1-phosphate in the vascular system.Tumor-suppressive sphingosine-1-phosphate receptor-2 counteracting tumor-promoting sphingosine-1-phosphate receptor-1 and sphingosine kinase 1 - Jekyll Hidden behind HydeSphingolipid and glycosphingolipid metabolic pathways in the era of sphingolipidomics.Emerging biology of sphingosine-1-phosphate: its role in pathogenesis and therapy.Regulation of mammalian physiology, development, and disease by the sphingosine 1-phosphate and lysophosphatidic acid receptors.Cbl-b-deficient mice express alterations in trafficking-related molecules but retain sensitivity to the multiple sclerosis therapeutic agent, FTY720.Visualizing S1P-directed cellular egress by intravital imagingLymph node B lymphocyte trafficking is constrained by anatomy and highly dependent upon chemoattractant desensitization.Biocomparison of Three Formulations of the S1P1 Receptor Modulator Ponesimod in Healthy Subjects.HDL-bound sphingosine-1-phosphate restrains lymphopoiesis and neuroinflammation.Regulation of acute graft-versus-host disease by microRNA-155.The outs and the ins of sphingosine-1-phosphate in immunityIntravital Two-Photon Imaging of Lymphocytes Crossing High Endothelial Venules and Cortical Lymphatics in the Inguinal Lymph Node.The sphingosine-1-phosphate analogue FTY720 impairs mucosal immunity and clearance of the enteric pathogen Citrobacter rodentium.Communication between host organism and cancer cells is transduced by systemic sphingosine kinase 1/sphingosine 1-phosphate signalling to regulate tumour metastasis.S1P and the birth of platelets.T cell-intrinsic S1PR1 regulates endogenous effector T-cell egress dynamics from lymph nodes during infection.S1P₁ localizes to the colonic vasculature in ulcerative colitis and maintains blood vessel integrity.Fine-tuning S1P therapeuticsBioactive lipids and cationic antimicrobial peptides as new potential regulators for trafficking of bone marrow-derived stem cells in patients with acute myocardial infarction.Mechanism of Action and Clinical Potential of Fingolimod for the Treatment of Stroke.Therapeutic dosing of fingolimod (FTY720) prevents cell infiltration, rapidly suppresses ocular inflammation, and maintains the blood-ocular barrier.
P2860
Q24609856-179A5147-413B-4D37-AD20-8B63E530A332Q26748848-4B9C8A43-BCE8-41B9-B0BE-CC315075A9F1Q27011857-0C1374DF-0569-4179-B75B-530D4DC482BCQ27026175-59FF2A35-694C-4724-9011-7671102CD150Q27342788-144331FC-E23F-4CD1-A510-B31361A18035Q28553993-0DFBCC62-69EF-4FCC-8B69-B98CBE2DBB63Q30416979-EF33A8FC-62CA-4A0E-99EF-4B887937DF0DQ33583306-6D257810-E00A-41FD-8BD8-4485CC0C66E8Q33795328-6CDED4B3-0629-46D0-B9F9-DA1CF9A71A11Q34089093-F68E7688-3FFE-4FB1-B7F3-6DE14F2C50FFQ34150336-A3471A19-6479-41A6-95BE-A895C471D025Q34396876-CA56F418-632A-4AE3-AC58-1F3E33B64AD0Q34442025-C71AC5D6-DAAE-4E93-9FD0-067B2DC021ECQ34474363-B700B007-90F2-4E4E-A757-2659D4506E63Q34518822-578A0CD7-76B3-4C07-A622-74AA5BB000C6Q34565310-6F576BC1-72D3-4781-A79F-D601496DF36BQ34664459-FFC11F37-C470-4FF0-B1F2-819D28478B46Q35126954-F776FE0F-FA5F-49AE-8989-F496C6E0D637Q35130512-CE1DC8E7-6651-499B-9275-FA15B2FB8B6BQ35264010-CD79B252-100E-42C5-BB61-CB6CC2B8DCB5Q35324757-96AD394B-07A9-45BB-B13A-29E4BAC80BE0Q35535621-6FDF5EBB-1958-40BA-AE14-C57A84B93C1DQ35551835-1C1A6EC0-FC0E-4E1E-92DD-31BF8587D84BQ35572346-E134719C-EF66-4B50-A6D2-F4F2A292ED03Q35673151-22349F0A-2670-4084-855A-AABCDD0986B1Q35733802-BCA16C3D-FED4-4C42-9C83-DAA875CED7CDQ35807339-AC588A07-1F92-43DC-B4A6-C924C368C229Q35862820-782381F2-361A-45AC-957A-092FCFA87032Q36010229-7680E815-FA66-454F-9637-28108D8DAE74Q36011196-4993FDDD-55FA-4F96-BBDB-D11CA002AF1CQ36043665-6DF38C1F-F906-4D2B-BECE-60E3B511BFCEQ36211058-4FFD862E-3E80-4CF9-B9A7-898761AAE013Q36386459-68284E9D-DAF5-404B-8CD4-E231E7B984E4Q36409037-E0382CE5-8A69-497A-A571-31B8E08A7292Q36646448-74B836DF-AAA4-41D9-BCA2-7A182EC3A432Q36744155-C00FDF4C-2FCC-49ED-8736-1D707C2B538EQ36762973-9940DB7C-D279-4E16-BAD5-E16BACA90620Q36853117-1558469C-A069-4741-ADC7-359CA8C673BFQ37209163-8102B7E5-8B96-45E5-A7B7-815A46B21A67Q37229011-81FD52ED-5926-472F-8DAD-FA1353CB6C82
P2860
Cell-surface residence of sphingosine 1-phosphate receptor 1 on lymphocytes determines lymphocyte egress kinetics.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Cell-surface residence of sphi ...... es lymphocyte egress kinetics.
@ast
Cell-surface residence of sphi ...... es lymphocyte egress kinetics.
@en
type
label
Cell-surface residence of sphi ...... es lymphocyte egress kinetics.
@ast
Cell-surface residence of sphi ...... es lymphocyte egress kinetics.
@en
prefLabel
Cell-surface residence of sphi ...... es lymphocyte egress kinetics.
@ast
Cell-surface residence of sphi ...... es lymphocyte egress kinetics.
@en
P2093
P2860
P356
P1476
Cell-surface residence of sphi ...... es lymphocyte egress kinetics.
@en
P2093
Caiying Guo
Dong-Soon Im
Kamal M Khanna
Leo Lefrancois
Myat Lin Oo
Shobha Thangada
Timothy Hla
Victoria A Blaho
P2860
P304
P356
10.1084/JEM.20091343
P407
P577
2010-06-28T00:00:00Z